File S1 - <i>KIR</i>, <i>HLA</i>, and <i>IL28B</i> Variant Predict Response to Antiviral Therapy in Genotype 1 Chronic Hepatitis C Patients in Japan

Table S1, Sensitivity, specificity, and predictive values of IL28B TT genotype and KIR3DL1/HLA-Bw4 or KIR2DL2/HLA-C1 for a sustained virological response in 115 patients with chronic hepatitis C. Data are expressed as % (n). PPV, positive predictive value; NPV, negative predictive value. Table S2, Frequency of IL28B genotype and KIR3DL1/HLA-Bw4 and KIR2DL2/HLA-C1 combinations in 56 patients with a sustained virological response (SVR) and 59 patients with a non-SVR to pegylated interferon and ribavirin therapy of chronic hepatitis C. Data are expressed as n (%). (DOC)表S1：115例慢性丙型肝炎患者中，IL28B TT基因型、KIR3DL1/HLA-Bw4或KIR2DL2/HLA-C1与持续病毒学应答（Sustained Virological Response，SVR）的灵敏度、特异度及预测价值。数据以%（n）形式呈现。其中PPV为阳性预测值（Positive Predictive Value，PPV），NPV为阴性预测值（Negative Predictive Value，NPV）。 表S2：56例接受慢性丙型肝炎聚乙二醇干扰素联合利巴韦林治疗并获得持续病毒学应答（Sustained Virological Response，SVR）的患者，以及59例同期接受相同治疗但未获得持续病毒学应答的患者中，IL28B基因型、KIR3DL1/HLA-Bw4与KIR2DL2/HLA-C1组合的分布频率。数据以n（%）形式呈现。 (DOC)